Brought to you by 
Anokion allies with Astellas and forms Kanyos to develop compounds
13 Sep 2019
Executive Summary
Astellas Pharma Inc. and Anokion SA are teaming up to develop compounds for Type I diabetes and celiac disease. Anokion created Kanyos Bio Inc. to develop the candidates and the spin-off concurrently raised $16mm from Astellas, individual investors, and Anokion's Series A backers Versant Ventures, Novo Ventures, and Novartis Venture Fund.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes M&A Option
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Anokion allies with Astellas and forms Kanyos to develop compounds
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice